Skip to content
lifestyle.womensconference.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Novo Nordisk A/S
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
September 29, 2026
Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly
July 21, 2026
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
February 10, 2026